Øystein Fløtten

Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Bjørn Henning Grønberg, Roy M. Bremnes, Øystein Fløtten et al. · Journal of Clinical Oncology · 2009 · 290 citations · Full text

Medicine, Oncology, Pharmacology +16

Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer

Manash Chatterjee, David C. Turner, Enriqueta Felip et al. · Annals of Oncology · 2016 · 162 citations · Full text

Medicine, Oncology, Pharmacology +12

Muscle mass and association to quality of life in non‐small cell lung cancer patients

Asta Bye, Bjørg Sjøblom, Tore Wentzel‐Larsen et al. · Journal of Cachexia Sarcopenia and Muscle · 2017 · 147 citations · Full text

Medicine, Oncology, Radiology +14

Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer

Bjørg Sjøblom, Bjørn Henning Grønberg, Tore Wentzel‐Larsen et al. · Clinical Nutrition · 2016 · 145 citations

Medicine, Oncology, Radiology +9

High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial

Bjørn Henning Grønberg, Kristin Toftaker Killingberg, Øystein Fløtten et al. · The Lancet Oncology · 2021 · 138 citations · Full text

Medicine, Oncology, Radiation Oncology +11